Plasma D-Dimer Measurement as a Marker of Gynecologic Tumors: Comparison with CA 125

Rella, C.; Coviello, M.; N, De Frenza; Falco, Gaetano; Chiuri, E; Colavito, Paolo; Quaranata, M; A, De Leonardis

doi:10.1177/030089169307900513

Cited by 22 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 7 studies [22,24–26,32–34] involving 366 ovarian cancer patients and 233 benign controls investigated the association between D-dimer and ovarian cancer. Our results showed that patients with ovarian cancer (stages I–IV) showed a higher D-dimer level compared with benign controls (SMD = 0.774, 95% CI: 0.597–0.951), with low degree of heterogeneity ( P = .390, I 2 = 4.9%, Fig.…”

Section: Resultsmentioning

confidence: 99%

Clinical significance of plasma D-dimer in ovarian cancer

Liu

et al. 2017

Medicine

View full text Add to dashboard Cite

Background:D-dimer has been widely used for the diagnosis and prognosis of ovarian cancer, but there is still controversy on its prediction value of ovarian cancer.Objectives:To explore the clinical significance of plasma D-dimer level on ovarian cancer systematically.Methods:Using PubMed, Cochrane Library, and Web of Science libraries, all the relevant studies for the diagnostic and prognostic value of plasma D-dimer for ovarian cancer and the relationship between elevated D-dimer level and venous thromboembolism (VTE) risk of ovarian cancer were searched till May 30, 2016. Standardized mean difference (SMD), odds ratio (OR), hazard ratio (HR), and 95% confidence interval (CI) were appropriately pooled.Results:A total of 15 eligible studies involving a total of 1437 cancer patients were included. No significant association was found between high D-dimer level and overall survival of patients with ovarian cancer (HR 1.32, 95% CI: 0.90–1.95, P = .044). However, subgroup analysis indicated that the sample sizes could explain the heterogeneity between studies. And elevated D-dimer could predict increased risk of mortality when the sample sizes were >100 (HR 1.800, 95% CI: 1.283–2.523, P = .845). Besides, plasma D-dimer level was significantly higher in malignant ovarian cancer patients compared with benign controls (SMD 0.774, 95% CI: 0.597–0.951, P = .39), higher in advanced ovarian cancer patients (International Federation of Gynecology and Obstetrics [FIGO] classification III and IV) than in early stage ovarian cancer patients (FIGO classification I and II, SMD 0.611, 95% CI: 0.373–0.849, P = .442). And high D-dimer level indicated high VTE risk (OR 4.068, 95% CI: 2.423–6.829, P = .629) of ovarian cancer patients.Conclusion:The plasma D-dimer level in ovarian cancer patients can predict the changes that correlated with disease progression and the VTE risk. But its predictive value for the prognosis of ovarian cancer was significantly dependent on the sample sizes. More well-designed studies with large sample sizes are needed to validate and update the findings of present study.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical significance of plasma D-dimer in ovarian cancer

Liu

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…32 It is a sensitive marker of the fibrinolytic enhancement. 32 As in many other human malignancies, [33][34][35][36][37][38] including lung carcinoma, DD might have prognostic significance. 12,15,39 In 1993, Seitz et al 12 reported that TAT and DD were significantly increased in patients with metastatic disease and that elevated TAT values at diagnosis might be prognostically significant.…”

Section: Discussionmentioning

confidence: 99%

Plasma levels of D‐dimer in lung carcinoma

Buccheri

Torchio

Ferrigno

2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe activation of the clotting‐fibrinolytic system in cancer patients is common and represents an unfavorable clinical sign. D‐dimer (DD) is a sensitive marker of fibrinolysis.METHODSThe current study comprised 826 new lung carcinoma patients seen consecutively in a single institution over a 10‐year period (1992–2001). For each patient, 31 variables, including DD and survival duration, were available for analysis.RESULTSOnly weak relationships between DD and the other variables were found. The DD variable correlated best with the level of lactate dehydrogenase, performance status, tissue polypeptide antigen, stage of disease, and the number of metastases (rho = 0.33, −0.25, 0.18, 0.18, and 0.15, respectively). The D‐dimer distinguished patients with different prognoses. The median survival periods were 154 days (95% confidence interval [CI], 122–189 days) and 308 days (95% CI, 227–409 days; log rank statistic, 26.56; P < 0.01), respectively, for abnormally elevated and normal values. The difference was greater in patients with adenocarcinoma and in patients presenting with a less advanced disease, especially in patients with pathologic Stage Ia disease. The best multivariate survival model selected 10 significant covariates, including DD.CONCLUSIONSThe authors recommend measuring the plasma level of DD in all new lung carcinoma patients. This measurement may help to formulate individual prognoses and can be used to indicate adjuvant treatment for surgical patients. Cancer 2003;97:3044–52. © 2003 American Cancer Society.DOI 10.1002/cncr.11432

show abstract

“…Thus, d ‐dimer is considered a marker for hypercoagulopathy. Indeed, elevated plasma d ‐dimer concentrations correlate with tumor progression in various malignancies, including esophageal cancer, lung cancer, colorectal cancer, ovarian cancer, cervical cancer of the uterus, and prostate cancer 17–22 . Recent data have suggested that antithrombotic therapy, such as platelet inhibitors, heparin, and low molecular weight heparin, may affect tumor progression.…”

Section: Introductionmentioning

confidence: 99%

“…Indeed, elevated plasma -dimer concentrations correlate with tumor progression in various malignancies, including esophageal cancer, lung cancer, colorectal cancer, ovarian cancer, cervical cancer of the uterus, and prostate cancer. [17][18][19][20][21][22] Recent data have suggested that antithrombotic therapy, such as platelet inhibitors, heparin, and low molecular weight heparin, may affect tumor progression. In fact, several studies have suggested that the combination of chemotherapy and antithrombotic agents could prolong survival of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Correlation between pretherapeutic d-dimer levels and response to neoadjuvant chemotherapy in patients with advanced esophageal cancer

et al. 2008

View full text Add to dashboard Cite

Neoadjuvant chemotherapy may improve survival of responders in esophageal cancer patients but is useless and harmful in non-responders. Thus, it is important to predict the effect of the chemotherapy, and that any predictor must be applicable clinically. The aim of this study is to examine the correlation between pretherapeutic hypercoagulopathy as determined by plasma d-dimer levels and response to chemotherapy. In 71 patients with esophageal cancer who underwent neoadjuvant chemotherapy (cisplatin, adriamycin and 5-fluorouracil) followed by surgery, plasma d-dimer levels were measured before chemotherapy and the clinical and pathological responses to chemotherapy were assessed at 4 weeks after therapy (after surgery). Pretherapeutic plasma d-dimer level was significantly lower in clinical responders (complete response/partial response [CR/PR]; 0.62 +/- 1.10 microg/mL, mean +/- SD) than in non-responders (no change/progressive disease [NC/PD]; 1.15 +/- 1.08 microg/mL, P = 0.0491), and in pathological responders (Grade 1b-3; 0.62 +/- 1.11 microg/mL) and non-responders (Grade 0-1a; 1.15 +/- 1.05 microg/mL, P = 0.0107). The optimal cut-off level of the plasma d-dimer levels for predicting clinical and pathological responses was 0.6 microg/mL. Then, sensitivity and specificity for the prediction of CR/PR were 68% and 73%, and those for Grade 1b-3 were 91% and 69%, respectively. Our results suggested that pretherapeutic plasma d-dimer level correlated significantly with clinical and pathological responses to chemotherapy. Pretherapeutic plasma d-dimer level can be used as a predictor for chemosensitivity.

show abstract

Plasma D-Dimer Measurement as a Marker of Gynecologic Tumors: Comparison with CA 125

Abstract: Our results suggest that D-dimer can serve as a sensitive indicator to monitor the extent and course of the disease in ovarian cancer patients. The patient follow-up is ongoing to establish the predictive value of D-dimer measurement with respect to prognosis.

Cited by 22 publications

References 17 publications

Clinical significance of plasma D-dimer in ovarian cancer

Clinical significance of plasma D-dimer in ovarian cancer

Plasma levels of D‐dimer in lung carcinoma

Correlation between pretherapeutic d-dimer levels and response to neoadjuvant chemotherapy in patients with advanced esophageal cancer

Contact Info

Product

Resources

About